TY - JOUR
T1 - Regulatory T cells in acute myelogenous leukemia
T2 - Is it time for immunomodulation?
AU - Ustun, Celalettin
AU - Miller, Jeffrey S.
AU - Munn, David H.
AU - Weisdorf, Daniel J.
AU - Blazar, Bruce R.
PY - 2011/11/10
Y1 - 2011/11/10
N2 - The microenviroment of acute myelogenous leukemia (AML) is suppressive for immune effector cells. Regulatory T cells (Tregs) have been recognized as a contributor factor and may be recruited and exploited by leukemic cells to evade immunesurveillance. Studies have shown that the frequencies of marrow and blood Tregs are greater in patients with AML than in control patients. Although increased Tregs have been associated with a decreased risk of GVHD after allogeneic HCT and hence may impede the graft-versus-tumor effect, recent findings indicate that that this may not be the case. Because there is a need to improve outcomes of standard treatment (chemotherapy with or without allogeneic HCT) in AML, targeting Tregs present an outstanding opportunity inAML because discoveries may apply throughout its treatment. Here, we review data on the roles of Tregs in mediating immune system-AML interactions. We focused on in vitro, animal, and observational human studies of Tregs inAML biology, development, prognosis, and therapy in different settings (eg, vaccination and HCT). Manipulation of Tregs or other types of immunomodulation may become a part of AML treatment in the future.
AB - The microenviroment of acute myelogenous leukemia (AML) is suppressive for immune effector cells. Regulatory T cells (Tregs) have been recognized as a contributor factor and may be recruited and exploited by leukemic cells to evade immunesurveillance. Studies have shown that the frequencies of marrow and blood Tregs are greater in patients with AML than in control patients. Although increased Tregs have been associated with a decreased risk of GVHD after allogeneic HCT and hence may impede the graft-versus-tumor effect, recent findings indicate that that this may not be the case. Because there is a need to improve outcomes of standard treatment (chemotherapy with or without allogeneic HCT) in AML, targeting Tregs present an outstanding opportunity inAML because discoveries may apply throughout its treatment. Here, we review data on the roles of Tregs in mediating immune system-AML interactions. We focused on in vitro, animal, and observational human studies of Tregs inAML biology, development, prognosis, and therapy in different settings (eg, vaccination and HCT). Manipulation of Tregs or other types of immunomodulation may become a part of AML treatment in the future.
UR - http://www.scopus.com/inward/record.url?scp=81055148087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81055148087&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-07-365817
DO - 10.1182/blood-2011-07-365817
M3 - Review article
C2 - 21881045
AN - SCOPUS:81055148087
SN - 0006-4971
VL - 118
SP - 5084
EP - 5095
JO - Blood
JF - Blood
IS - 19
ER -